Inveready et al. invest €380k in Proretina

The four private equity firms each invested €95,000 in the company, which develops pharmaceuticals for the treatment of diseases affecting the retina.

The deal meant each of the investors increased their equity stake from 8.6% to 12.5%.

The unquote" team is currently researching this transaction. In-depth deal information for subscribers will follow shortly.

If you have any information regarding this transaction, please contact Susannah Birkwood on +44 20 7004 7524 or susannah.birkwood@incisivemedia.com

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Southern Europe
• Healthcare
• Expansion